Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing.
Lenz L, Clegg W, Iliev D, Kasten CR, Korman H, Morgan TM, Hafron J, DeHaan A, Olsson C, Tutrone RF Jr, Richardson T, Cline K, Yonover PM, Jasper J, Cohen T, Finch R, Slavin TP Jr, Gutin A.
Lenz L, et al. Among authors: kasten cr.
Prostate Cancer Prostatic Dis. 2025 Jun;28(2):427-434. doi: 10.1038/s41391-024-00888-y. Epub 2024 Sep 5.
Prostate Cancer Prostatic Dis. 2025.
PMID: 39237680
Free PMC article.